ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients’ quality of life

Published July 22, 2010

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients’ quality of life
Results from the landmark AIDS Treatment for Life International Survey, a multi-country survey of more than 2,000 people living with HIV/AIDS, revealed a significant gap in patient-physician dialogue about critical health-related conditions that may negatively impact patients’ overall long-term health, quality of life, and treatment outcomes.
Read more on News-Medical-Net

FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review
Eisai Inc. (Headquarters: Woodcliff Lake, NJ; President and CEO: Lonnel Coats), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL). The proposed indication is for the adjunctive treatment of seizures associated …
Read more on Medical News Today